Key Details
Annual ROE
-53.63%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 07, 2023Recent annual earnings:
Mar 14, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
18 July '23 JMP Securities
Market Perform04 Apr '23 SVB Leerink
Market Perform15 Mar '23 JMP Securities
Market Outperform27 Jan '23 SVB Leerink
Outperform13 Dec '22 JMP Securities
Market Outperform16 Aug '22 SVB Leerink
Outperform15 Mar '22 SVB Leerink
Outperform18 Jan '22 Jefferies
BuyScreeners with PRDS included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Pardes Biosciences doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Pardes Biosciences stock rallies on buyout offer from MediPacific
PRDS
Market Watch17 July 2023
Pardes Biosciences Inc.'s PRDS, -0.54% stock was up 12.4% in premarket trades Monday after the clinical-stage biopharmaceutical company said it agreed to be acquired by MediPacific Inc. for up to $2.19 a share. The purchase price is not less than $2.02 a share in cash and an additional cash amount of not more than 17 cents per share, with the final price per share being based on the amount of the company's net cash at closing, plus a non-tradeable contingent-value right associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.
All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy
PRDS
Zacks Investment Research05 June 2023
Pardes Biosciences, Inc. (PRDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pardes Biosciences Seeking Strategic Alternatives
PRDS
Seeking Alpha17 May 2023
Pardes Biosciences Seeking Strategic Alternatives. Pardes' Pipeline is depleted.
FAQ
- What is the primary business of Pardes Biosciences?
- What is the ticker symbol for Pardes Biosciences?
- Does Pardes Biosciences pay dividends?
- What sector is Pardes Biosciences in?
- What industry is Pardes Biosciences in?
- What country is Pardes Biosciences based in?
- When did Pardes Biosciences go public?
- Is Pardes Biosciences in the S&P 500?
- Is Pardes Biosciences in the NASDAQ 100?
- Is Pardes Biosciences in the Dow Jones?
- When was Pardes Biosciences's last earnings report?
- When does Pardes Biosciences report earnings?
- Should I buy Pardes Biosciences stock now?
What is the primary business of Pardes Biosciences?
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.
What is the ticker symbol for Pardes Biosciences?
The ticker symbol for Pardes Biosciences is NASDAQ:PRDS
Does Pardes Biosciences pay dividends?
No, Pardes Biosciences does not pay dividends
What sector is Pardes Biosciences in?
Pardes Biosciences is in the Healthcare sector
What industry is Pardes Biosciences in?
Pardes Biosciences is in the Biotechnology industry
What country is Pardes Biosciences based in?
Pardes Biosciences is headquartered in United States
When did Pardes Biosciences go public?
Pardes Biosciences's initial public offering (IPO) was on 27 December 2021
Is Pardes Biosciences in the S&P 500?
No, Pardes Biosciences is not included in the S&P 500 index
Is Pardes Biosciences in the NASDAQ 100?
No, Pardes Biosciences is not included in the NASDAQ 100 index
Is Pardes Biosciences in the Dow Jones?
No, Pardes Biosciences is not included in the Dow Jones index
When was Pardes Biosciences's last earnings report?
Pardes Biosciences's most recent earnings report was on 7 November 2023
When does Pardes Biosciences report earnings?
The date for Pardes Biosciences's next earnings report has not been announced yet
Should I buy Pardes Biosciences stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions